These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9255776)

  • 1. ICH-4 sets course for global harmony.
    Davidson S
    Nat Biotechnol; 1997 Aug; 15(8):711-2. PubMed ID: 9255776
    [No Abstract]   [Full Text] [Related]  

  • 2. ICH activities on biotech topics.
    Zorzi-Morre P
    Dev Biol Stand; 1999; 100():151-3. PubMed ID: 10616186
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contribution of explanatory notes. Efficacy of the ICH plan for international clinical development of a new drug].
    Husson JM
    Ann Pharm Fr; 1999 Mar; 57(2):153-60. PubMed ID: 10365472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent progress of the international harmonization of toxicological testing: impact and implementation of ICH guidelines. International Conference Harmonization.
    Igarashi T
    J Toxicol Sci; 1998 Jul; 23 Suppl 2():255-7. PubMed ID: 9760477
    [No Abstract]   [Full Text] [Related]  

  • 9. International Conference on Harmonisation; Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Feb; 73(35):9575-6. PubMed ID: 18677819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines from the International Conference on Harmonisation (ICH).
    Branch SK
    J Pharm Biomed Anal; 2005 Aug; 38(5):798-805. PubMed ID: 16076542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the Gap in International Norms for Biosafety.
    Gronvall GK; Rozo M
    Trends Microbiol; 2015 Dec; 23(12):743-744. PubMed ID: 26654137
    [No Abstract]   [Full Text] [Related]  

  • 13. Patent pools and standard setting in diagnostic genetics.
    Ebersole TJ; Guthrie MC; Goldstein JA
    Nat Biotechnol; 2005 Aug; 23(8):937-8. PubMed ID: 16082359
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Conference on Harmonisation; guidance on M4 common technical document; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Oct; 66(200):52634-7. PubMed ID: 12358037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 20-year African biotech plan.
    Singh JA; Daar AS
    Nat Biotechnol; 2008 Mar; 26(3):272-4. PubMed ID: 18327231
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In defense of the precautionary principle.
    Raffensperger C; Barrett K
    Nat Biotechnol; 2001 Sep; 19(9):811-2. PubMed ID: 11533632
    [No Abstract]   [Full Text] [Related]  

  • 20. Compromise sought over germplasm access.
    Putterman D
    Nature; 1994 Nov; 372(6501):9. PubMed ID: 7969424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.